CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies CAMBRIDGE, Mass. — Cullinan Therapeutics,...
Latest News
NEW YORK, NY — Newly published research in the journal Glia has identified crucial links between dietary choices and the progression of multiple sclerosis (MS). The study, led by Patrizia Casaccia, founding director of the Advanced Science Research Center at the CUNY Graduate Center’s (CUNY ASRC) Neuroscience Initiative and Einstein...
SAN CARLOS, Calif. — CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial in neurogenic orthostatic hypotension (nOH). nOH is a serious condition characterized by...
New York, NY – Cure Mito Foundation and Hope for PDCD foundation, both patient-led foundations focused on advancing research and supporting families affected by Leigh syndrome and Pyruvate Dehydrogenase Complex Deficiency (PDCD), respectively, are excited to announce a launch of a PDCD patient registry. This innovative registry will be led...
WOODBRIDGE, Conn. — Cure Rare Disease (CRD) announced it has been awarded a $7.4 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of a novel gene therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), a progressive neuromuscular disorder with limited treatment options. Cure Rare...
WOODBRIDGE, Conn. — Cure Rare Disease (CRD), a 501(c)(3) nonprofit biotechnology company developing genetic therapies for ultra-rare neuromuscular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its investigational therapy, CRD-003, for the treatment of congenital muscular dystrophy caused by biallelic...
NEWPORT BEACH, Calif., March 18, 2021 — CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a webinar to continue educating the Duchenne community about the COVID-19 vaccines. Part of their COVID-19 education initiative which launched in January, this webinar will focus...
NEWPORT BEACH, Calif. – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, today launched a supplemental newborn screening initiative for Duchenne muscular dystrophy, a rare genetic disorder. The partnership between CureDuchenne and Brigham and Women’s Hospital is the first program to offer supplemental newborn screening...
NEWPORT BEACH, Calif. and EDMONTON, AB — CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing its non-viral, redosable Fusogenix PLV delivery platform. Entos will use this funding to create a muscle-targeting therapeutic to deliver full-length dystrophin for the treatment of Duchenne...
BOSTON – CureLab Oncology, a clinical-stage biotech company, has been granted a US patent for the application of its lead product for the treatment of ALS, Alzheimer’s, Huntington’s, and Parkinson’s disease. These patent applications were already granted in Asia and Europe. Today, 5 million Americans suffer from Alzheimer’s, 1 million from Parkinson’s, 30,000...